Trinity Biotech Plc, Bray, Ireland, recently submitted to FDA an application for premarket notification (510(k)) clearance for its Meritas point-of-care (POC) analyzer and Meritas cardiac troponin I (cTnI) POC assay for use in the diagnosis of myocardial infarction. The single-use, precalibrated cTnI assay, which is run on the Meritas analyzer, was developed to assist healthcare professionals in quickly determining patient cardiac status in emergency department settings. Delivering cTnI results in about 15 minutes from either whole blood or plasma samples, the assay combines sensitive antibody reagents and the use of advanced injection molding technologies to create high-fidelity micropillar structures to control sample fluidics. For more information, visit Trinity Biotech.